EPO primary response gene, EPRG3Spt

Details EPO primary response gene, EPRG3Spt EPO primary response gene, EPRG3Spt

2000-01-31

2001-10-23

Jones, W. Gary (Department: 1655)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S005000, C435S091100, C435S091200, C536S022100

Reexamination Certificate

active

06306604

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genornics’, that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genornics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to EPRG3Spt, in particular EPRG3Spt polypeptides and EPRG3Spt polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of anemia, polycythemia, cancer; AIDS, and drug-induced anemias, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with EPRG3Spt imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate EPRG3Spt activity or levels.


REFERENCES:
patent: WO9906442 (1999-05-01), None
Kelly, J.M. et al., “Characterization of a human gene inducible by &agr;- and &bgr;- interferons and its expression in mouse cells”, The EMBO Journal, vol. 5 (7), pp. 1601-1606 (1986).
Copy of International Search Report.
Rasmussen et al. “Identification of a New Interferon-a-inducible Gene on Human Chromosome 14q32 And Its Expression in Breast Carcinoma” Cancer Research, vol. 53, pp. 4096-4101 (1993).

Affiliated with

Also associated with

Rating

EPO primary response gene, EPRG3Spt does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EPO primary response gene, EPRG3Spt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EPO primary response gene, EPRG3Spt will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2566972